We have biosimilars coming … Plans at MerckSerono
June 2010. With more challenges ahead to face the lower cost environment of medical health care, pharma process development has to ensure peak process performance, availability of alternative upstream technologies, as well as adapting these to industrial scale. In the interview with B2Bioworld Jonathan Barnsley, Senior Vice President, Biotech Manufacturing and Process Development Merck Serono, describes opportunities and threats.
Includes Merck Serono Pipeline April 2010; Overview Technical and Manufacturing Operations Worldwide.Reading time: 4 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Merck Life Science: Make or Break Drug Discovery and Biopharma
Andrew Bulpin, Global Head of Merck Millipore Process Solutions on strategy, competitors, and the road ahead